These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1746921)

  • 1. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.
    Repetto L; Chiara S; Guido T; Bruzzone M; Oliva C; Ragni N; Conte PF; Rosso R
    Anticancer Res; 1991; 11(4):1641-3. PubMed ID: 1746921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer.
    Ferrari E; Maffeo DA; Graziano R; Gallo MS; Pignata S; De Rosa L; Montella M; Pergola M
    Eur J Gynaecol Oncol; 1994; 15(6):437-42. PubMed ID: 7875158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
    Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P
    Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study.
    Frasci G; Tortoriello A; Facchini G; Conforti S; Persico G; Mastrantonio P; Cardone A; Iaffaioli RV
    Eur J Cancer; 1994; 30A(7):946-50. PubMed ID: 7946589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
    Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi PG; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte PF
    Gynecol Oncol; 1997 Jun; 65(3):499-505. PubMed ID: 9190982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
    Guastalla JP; Lhomme C; Kerbrat P; Mayer F; Namer M; Goupil P; Charrot P; Heron JF; Chazard M; Richard I
    Ann Oncol; 1994 Feb; 5(2):127-32. PubMed ID: 8186155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
    Muggia FM; Jeffers S; Muderspach L; Roman L; Rosales R; Groshen S; Safra T; Morrow CP
    Gynecol Oncol; 1997 Aug; 66(2):290-4. PubMed ID: 9264578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer?
    Markman M
    Oncology (Williston Park); 2001 Jan; 15(1):93-8; discussion 103-5. PubMed ID: 11271985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.
    Kim SW; Paek J; Nam EJ; Kim SH; Kim JH; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2010 Oct; 152(2):195-9. PubMed ID: 20576343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
    Nardi M; Cognetti F; Pollera CF; Giulia MD; Lombardi A; Atlante G; Calabresi F
    J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.